Immediately Injections of Botulinum Toxin A After Surgical Excision for Ear Keloids: A Retrospective Study.

IF 1 4区医学 Q3 SURGERY

Journal of Craniofacial Surgery Pub Date : 2024-10-01 DOI:10.1097/SCS.0000000000010649

Shu Hua Li, Xiu Juan Shan, Zhen Hua Wang, Shu Jie Tao

{"title":"Immediately Injections of Botulinum Toxin A After Surgical Excision for Ear Keloids: A Retrospective Study.","authors":"Shu Hua Li, Xiu Juan Shan, Zhen Hua Wang, Shu Jie Tao","doi":"10.1097/SCS.0000000000010649","DOIUrl":null,"url":null,"abstract":"Background: Ear keloids are pathologic scar hyperplasia in the ear region. The most therapeutic approach was surgical shave excision with radiation therapy. However, radiation therapy is easily delivered to healthy surrounding tissues. In the last years, injections with botulinum toxin type A (BTX-A) have been proven to improve surgical scars effectively in clinical trials. This study aimed to evaluate the effect of immediate injections of BTX-A after surgical excision for ear keloids.Methods: From January 2020 to January 2023, 33 consecutive patients with ear keloids were enrolled. All patients underwent scar excision and revision at the same time when they needed BTX-A. It was injected into surgical wound closure immediately after surgery. The results of this study were evaluated at follow-up from 7 to 18 months using the Vancouver Scar Scale (VSS) and the Visual Analogue Scale (VAS).Results: From January 2020 to January 2023, 33 patients received concomitant therapy of immediate injections of BTX-A after surgery for ear keloids. The patients were evaluated at follow-ups lasting 7 to 18 months. Only one case recurred within the follow-up period, and no adverse effects were reported.Conclusion: This study demonstrates that significant cosmetic outcomes in ear keloid treatment were achieved after early postsurgical BTX-A injections. The patients reported high satisfaction and few complications.","PeriodicalId":15462,"journal":{"name":"Journal of Craniofacial Surgery","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Craniofacial Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SCS.0000000000010649","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ear keloids are pathologic scar hyperplasia in the ear region. The most therapeutic approach was surgical shave excision with radiation therapy. However, radiation therapy is easily delivered to healthy surrounding tissues. In the last years, injections with botulinum toxin type A (BTX-A) have been proven to improve surgical scars effectively in clinical trials. This study aimed to evaluate the effect of immediate injections of BTX-A after surgical excision for ear keloids.

Methods: From January 2020 to January 2023, 33 consecutive patients with ear keloids were enrolled. All patients underwent scar excision and revision at the same time when they needed BTX-A. It was injected into surgical wound closure immediately after surgery. The results of this study were evaluated at follow-up from 7 to 18 months using the Vancouver Scar Scale (VSS) and the Visual Analogue Scale (VAS).

Results: From January 2020 to January 2023, 33 patients received concomitant therapy of immediate injections of BTX-A after surgery for ear keloids. The patients were evaluated at follow-ups lasting 7 to 18 months. Only one case recurred within the follow-up period, and no adverse effects were reported.

Conclusion: This study demonstrates that significant cosmetic outcomes in ear keloid treatment were achieved after early postsurgical BTX-A injections. The patients reported high satisfaction and few complications.

查看原文本刊更多论文

耳瘢痕手术切除后立即注射肉毒杆菌毒素 A：回顾性研究

背景：耳部瘢痕疙瘩是耳部病理性瘢痕增生。最常见的治疗方法是手术刮除，同时进行放射治疗。然而，放射治疗很容易伤及周围的健康组织。近年来，临床试验证明注射 A 型肉毒毒素（BTX-A）可有效改善手术疤痕。本研究旨在评估耳部瘢痕手术切除后立即注射BTX-A的效果：方法：2020 年 1 月至 2023 年 1 月，连续纳入 33 例耳瘢痕患者。所有患者在需要 BTX-A 时都同时接受了瘢痕切除和修整手术。术后立即在手术伤口闭合处注射 BTX-A。研究结果通过温哥华瘢痕量表（VSS）和视觉模拟量表（VAS）在7至18个月的随访中进行评估：2020年1月至2023年1月，33名患者在耳部瘢痕疙瘩手术后立即接受了BTX-A注射治疗。对患者进行了 7 至 18 个月的随访评估。只有一例患者在随访期间复发，没有不良反应报告：本研究表明，耳部瘢痕疙瘩术后早期注射 BTX-A 能取得明显的美容效果。患者满意度高，并发症少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Craniofacial Surgery 医学-外科

CiteScore

1.70

自引率

11.10%

发文量

968

审稿时长

1.5 months

期刊介绍： The Journal of Craniofacial Surgery serves as a forum of communication for all those involved in craniofacial surgery, maxillofacial surgery and pediatric plastic surgery. Coverage ranges from practical aspects of craniofacial surgery to the basic science that underlies surgical practice. The journal publishes original articles, scientific reviews, editorials and invited commentary, abstracts and selected articles from international journals, and occasional international bibliographies in craniofacial surgery.